Abstract
The human epidermal growth factor receptor (EGFR) biology is not completely explained; however EGFRtargeting has formed the basis of extensive and growing drug development. Inhibition of receptor tyrosine kinase activity involved in the EGFR signalling cascade is a fundamental mechanism for the use of EGFR specific tyrosine kinase (TK) inhibitors exemplified by gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva). Despite initially promising results in chemotherapy-resistant patients with non small cell lung cancer (NSCLC), disappointing results from phase III trials of gefitinib in NSCLC have been of concern of some. When EGFR-targeting drugs were introduced into the clinic, the specific targets affected in human tumors were unknown. Recently, different studies reported that mutations in the TK domain of EGFR are strongly associated with gefitinib- or erlotinib-sensitivity in patients with NSCLC. This article reviews the rationale for targeting EGFR by TK inhibitors, the discovery of EGFR mutations and subsequent studies to define the incidence, spectrum and functions of EGFR mutations. This paper represents the effort of a lung cancer focused translational research team made up of molecular biologists, medical oncologists and thoracic surgeons. The final objective is to achieve a comprehensive, but simple, review of the current status of the shift from cytotoxic to molecularly targeted therapy in lung cancer treatment potentially useful in the planning of translational research trials.
Keywords: EGFR family, Non-small cell lung cancer (NSCLC), cell proliferation, Gefitinib, OSI-774
Current Respiratory Medicine Reviews
Title: Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside
Volume: 3 Issue: 2
Author(s): Alessia Catassi, Alfredo Cesario, Pierluigi Granone and Patrizia Russo
Affiliation:
Keywords: EGFR family, Non-small cell lung cancer (NSCLC), cell proliferation, Gefitinib, OSI-774
Abstract: The human epidermal growth factor receptor (EGFR) biology is not completely explained; however EGFRtargeting has formed the basis of extensive and growing drug development. Inhibition of receptor tyrosine kinase activity involved in the EGFR signalling cascade is a fundamental mechanism for the use of EGFR specific tyrosine kinase (TK) inhibitors exemplified by gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva). Despite initially promising results in chemotherapy-resistant patients with non small cell lung cancer (NSCLC), disappointing results from phase III trials of gefitinib in NSCLC have been of concern of some. When EGFR-targeting drugs were introduced into the clinic, the specific targets affected in human tumors were unknown. Recently, different studies reported that mutations in the TK domain of EGFR are strongly associated with gefitinib- or erlotinib-sensitivity in patients with NSCLC. This article reviews the rationale for targeting EGFR by TK inhibitors, the discovery of EGFR mutations and subsequent studies to define the incidence, spectrum and functions of EGFR mutations. This paper represents the effort of a lung cancer focused translational research team made up of molecular biologists, medical oncologists and thoracic surgeons. The final objective is to achieve a comprehensive, but simple, review of the current status of the shift from cytotoxic to molecularly targeted therapy in lung cancer treatment potentially useful in the planning of translational research trials.
Export Options
About this article
Cite this article as:
Catassi Alessia, Cesario Alfredo, Granone Pierluigi and Russo Patrizia, Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside, Current Respiratory Medicine Reviews 2007; 3(2) . https://dx.doi.org/10.2174/157339807780599135
DOI https://dx.doi.org/10.2174/157339807780599135 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Functional Genomics- and Network-driven Systems Biology Approaches for Pharmacogenomics and Toxicogenomics
Current Drug Metabolism Marine Microbes-Derived Anti-Bacterial Agents
Mini-Reviews in Medicinal Chemistry Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art
Current Medicinal Chemistry Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets Chemical Modifications of Two Polysaccharides as Drug Carriers
Current Organic Synthesis Scheduling of Taxanes: A Review
Current Clinical Pharmacology Computational Approaches for Translational Oncology: Concepts and Patents
Recent Patents on Anti-Cancer Drug Discovery Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry The Role of Estrogen and Estrogen Receptors in Chemoresistance
Current Medicinal Chemistry Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience
Reviews on Recent Clinical Trials Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry The Protective Action of the Aqueous Extract of Auricularia polytricha in Paracetamol Induced Hepatotoxicity in Rats
Recent Patents on Drug Delivery & Formulation Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Tumor-Targeted Drug Delivery with Aptamers
Current Medicinal Chemistry Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology